Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL516909 | 0.92 | CNR1 (0.47) | MAPTMEN1KMT2ALMNAL3MBTL1 | |
| SCHEMBL516910 | 0.92 | CNR1 (0.47) | MAPTMEN1KMT2ALMNAL3MBTL1 | |
| SCHEMBL516949 | 0.83 | ALDH1A1 (0.50) | MEN1KMT2APOLBALDH1A1TP53 | |
| SCHEMBL516948 | 0.83 | ALDH1A1 (0.50) | MEN1KMT2APOLBALDH1A1TP53 | |
| SCHEMBL517554 | 0.82 | ALDH1A1 (0.56) | MAPTMEN1KMT2ALMNAPOLB | |
| SCHEMBL517555 | 0.82 | ALDH1A1 (0.56) | MAPTMEN1KMT2ALMNAPOLB | |
| SCHEMBL516920 | 0.80 | MAPT (0.53) | MAPTMEN1KMT2ALMNAL3MBTL1 | |
| SCHEMBL516919 | 0.80 | MAPT (0.53) | MAPTMEN1KMT2ALMNAL3MBTL1 | |
| SCHEMBL517107 | 0.78 | ALDH3A1 (0.44) | KMT2ALMNAPOLBALDH1A1TP53 | |
| SCHEMBL517108 | 0.78 | ALDH3A1 (0.44) | KMT2ALMNAPOLBALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9789118-B2 | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-10-17 | — | — | US | disclosed |
| US-20140171363-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| US-20120028969-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171363-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | ACACA, ACACB, COASY | MAPT 1271/4885MEN1 3950/4885KMT2A 2537/4885 |
| US-20120028969-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | ACACA, ACACB, COASY | MAPT 1271/4885MEN1 3950/4885KMT2A 2537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.